Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting the prostasin marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.
Prostasin, also known as channel activating protease 1, is a glycosyl-phosphatidyl-inositol (GPI)-anchored extracellular serine protease with the trypsin-like activity that cleaves synthetic substrates in vitro, preferentially at the carboxy terminus of arginine residues. Prostasin is abundantly expressed in normal epithelial cells and is essential for terminal epithelial cell differentiation. However, abnormal expression of prostasin is associated with many cancer types. Almost all cases of metastatic and hormone-refractory cancers show down-regulation of prostasin expression, indicating that prostasin may be a useful marker for tumor differentiation. Prostasin is involved in proteolytic cleavage of the extracellular domain of epithelial growth factor receptor (EGFR), causing a constitutively phosphorylated receptor that could potentially participate in tumor growth. Further research in this field demonstrates the potential role of prostasin as a cancer screening marker or as a therapeutic target for treating invasive and chemo-resistant tumors.
Many studies have reported the potential of prostasin as a marker for ovarian cancer (OVC). Costa et al. (2009) analyzed the mRNA expression of prostasin in fresh tumor samples of ovarian epithelial cancer by conventional and real-time quantitative PCR. The findings indicated that prostasin was overexpressed in many epithelial OVC. Tamir et al. (2016) assessed the cell-specific expression of prostasin by immunohistological tissue array analysis of normal, benign, and cancerous ovarian tissues and serum prostasin levels in normal, benign, and OVC serum samples. They found prostasin expression in OVC at levels more than 100-fold greater than found in normal or benign ovarian lesions. Also, significantly increased prostasin in sera of early-stage OVC, which can be sued as a screening biomarker for early-stage OVC.
Antibodies are core elements for antibody-based immunoassays for detecting and quantifying antigens of interest in different samples such as the serum, urine, tissue preparations, and so on. At Creative Biolabs, we offer a full range of antibody development, antigen & antibody conjugation, and IVD kit development services to clients across the globe. For more detailed information about what we offer for each stage of the development process, please click the links below:
Please feel free to contact us for more information and discuss your project needs.References
For Research Use Only.
